Loading…
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $139M | $-91M | $-107M | $-80M | -36.2% | 2.4% | 178.1% |
| 2024 | $135M | $-44M | $-39M | $-39M | -11.7% | 11.8% | 35.9% |
| 2023 | $121M | $-36M | $-28M | $-23M | -8.1% | 15.4% | -71.5% |
| 2022 | $105M | $-69M | $-100M | $-60M | -27.8% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 104.95 | 121.14 | 135.44 | 138.65 |
| Operating Revenue | - | 104.95 | 121.14 | 135.44 | 138.65 |
| Cost Of Revenue | - | 60.16 | 48.14 | 54.32 | 73.94 |
| Gross Profit | - | 44.79 | 73 | 81.12 | 64.72 |
| Operating Expense | - | 119.50 | 117.66 | 133.74 | 174.53 |
| Research And Development | - | 26.81 | 26.06 | 31.08 | 35.92 |
| Selling General And Administration | - | 93.26 | 92.82 | 104.64 | 138.85 |
| Total Expenses | - | 179.66 | 165.80 | 188.05 | 248.47 |
| Operating Income | - | -74.71 | -44.66 | -52.62 | -109.82 |
| Total Operating Income As Reported | - | -104.26 | -45.99 | -52.62 | -125.54 |
| EBITDA | - | -68.58 | -36.37 | -44.26 | -90.89 |
| Normalized EBITDA | - | -39.03 | -35.04 | -44.26 | -79.71 |
| EBIT | - | -74.71 | -44.66 | -52.62 | -109.82 |
| Interest Income | - | 5.13 | 15.84 | 14.66 | 8.57 |
| Net Interest Income | - | 5.13 | 15.84 | 14.66 | 8.57 |
| Other Non Operating Income Expenses | - | -0.28 | 2.52 | -0.14 | 0.16 |
| Other Income Expense | - | -29.83 | 1.19 | -0.14 | -11.02 |
| Interest Income Non Operating | - | 5.13 | 15.84 | 14.66 | 8.57 |
| Net Non Operating Interest Income Expense | - | 5.13 | 15.84 | 14.66 | 8.57 |
| Pretax Income | - | -99.41 | -27.64 | -38.10 | -112.27 |
| Tax Provision | - | 0.16 | 0.72 | 0.43 | -5.12 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -6.21 | -0.28 | 0 | -0.51 |
| Net Income Continuous Operations | - | -99.57 | -28.35 | -38.53 | -107.15 |
| Net Income From Continuing And Discontinued Operation | - | -99.57 | -28.35 | -38.53 | -107.15 |
| Net Income From Continuing Operation Net Minority Interest | - | -99.57 | -28.35 | -38.53 | -107.15 |
| Net Income | - | -99.57 | -28.35 | -38.53 | -107.15 |
| Net Income Common Stockholders | - | -99.57 | -28.35 | -38.53 | -107.15 |
| Net Income Including Noncontrolling Interests | - | -99.57 | -28.35 | -38.53 | -107.15 |
| Normalized Income | - | -76.22 | -27.30 | -38.53 | -96.48 |
| Diluted NI Availto Com Stockholders | - | -99.57 | -28.35 | -38.53 | -107.15 |
| Basic Average Shares | - | 36.99 | 37.59 | 38.37 | 42.64 |
| Diluted Average Shares | - | 36.99 | 37.59 | 38.37 | 42.64 |
| Reconciled Depreciation | - | 6.12 | 8.29 | 8.36 | 18.92 |
| Reconciled Cost Of Revenue | - | 60.16 | 48.14 | 54.32 | 73.94 |
| Total Unusual Items | - | -29.56 | -1.33 | 0 | -11.18 |
| Total Unusual Items Excluding Goodwill | - | -29.56 | -1.33 | 0 | -11.18 |
| Special Income Charges | - | -29.56 | -1.33 | 0 | -11.18 |
| Impairment Of Capital Assets | - | 29.56 | 1.33 | 0 | 15.73 |
| Restructuring And Mergern Acquisition | - | 3.76 | 0 | 0 | -4.55 |
| General And Administrative Expense | - | 93.26 | 92.82 | 104.64 | 138.85 |
| Other Gand A | - | 91.85 | 89.11 | 101.62 | 138.01 |
| Rent Expense Supplemental | - | 1.41 | 3.71 | 3.02 | 0.84 |
| Total Other Finance Cost | 0.40 | -5.13 | -15.84 | - | - |
| Other Operating Expenses | - | -0.57 | -1.23 | -1.98 | -0.24 |
| Selling And Marketing Expense | 92.34 | 92 | - | - | - |
| Rent And Landing Fees | - | 1.41 | 3.71 | 3.02 | 0.84 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Quanterix Corporationthis co. | QTRX | $179M | -1.67 | 0.61 | -36.2% | -2.05 |
| Cartesian Therapeutics, Inc. | RNAC | $192M | -1.48 | -1.52 | 103.2% | -0.96 |
| KORU Medical Systems, Inc. | KRMD | $190M | -72.09 | 11.15 | -15.5% | -85.47 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $189M | -1.53 | 0.77 | -50.6% | 0.14 |
| MediWound Ltd. | MDWD | $186M |
| - |
| - |
| - |
| - |
| - |
| - |
| -7.78 |
| 4.26 |
| -54.7% |
| -8.81 |
| Stereotaxis, Inc. | STXS | $184M | -8.49 | 13.63 | -160.5% | -8.55 |
| Journey Medical Corporation | DERM | $171M | -14.98 | 5.38 | -35.9% | -51.87 |
| Inogen, Inc. | INGN | $171M | -7.51 | 0.89 | -11.8% | -8.86 |
| ADC Therapeutics SA | ADCT | $168M | -1.18 | -0.90 | 76.7% | -0.27 |
| Peer Median | - | -7.64 | 2.57 | -25.7% | -8.68 | |